Journal of Diabetes and Its Complications
Volume 24, Issue 4 , Pages 229-233, July 2010

Gabapentin therapy improves heart rate variability in diabetic patients with peripheral neuropathy

  • Necip Ermis

      Affiliations

    • Cardiology Department, Baskent University Medical School, Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Cardiology Department, Adana Teaching and Medical Research Center, Baskent University, 01250 Yuregir, Adana, Turkey. Tel.: +90 322 3272727x2094; fax: +90 322 3271274.
  • ,
  • Hakan Gullu

      Affiliations

    • Cardiology Department, Baskent University Medical School, Ankara, Turkey
  • ,
  • Mustafa Caliskan

      Affiliations

    • Cardiology Department, Baskent University Medical School, Ankara, Turkey
  • ,
  • Aydan Unsal

      Affiliations

    • Endocrinology Department, Baskent University Medical School, Ankara, Turkey
  • ,
  • Mustafa Kulaksizoglu

      Affiliations

    • Endocrinology Department, Baskent University Medical School, Ankara, Turkey
  • ,
  • Haldun Muderrisoglu

      Affiliations

    • Cardiology Department, Baskent University Medical School, Ankara, Turkey

Received 15 July 2008; received in revised form 26 September 2008; accepted 3 December 2008. published online 06 February 2009.

Abstract 

Purpose

Diabetic cardiac neuropathy, which is characterized by reduced heart rate variability (HRV), frequently coexists with peripheral neuropathy. Gabapentin has been used for the treatment of diabetic neuropathy. We aimed to evaluate the possible effect of gabapentin treatment on autonomic function in patients with type 2 diabetes via HRV.

Methods

Thirty patients with type 2 diabetes mellitus and peripheral neuropathy and 28 age- and sex-matched healthy controls were consecutively registered. Each patient underwent HRV measurements, and diabetic patients were administered gabapentin. After 3 months of gabapentin therapy, HRV parameters were measured again.

Results

Baseline HRV parameters were blunted in patients with diabetes mellitus according to the controls [standard deviation of all NN intervals (SDNN, ms): 106.3±29.9 vs. 148.8±36.5, P=.001; power spectrum of the high-frequency band (HF, ms2): 133.6±98.3 to 231.4±197.6, P=.02; power spectrum of the low-frequency band (LF, ms2): 341.8±247.8 to 511.5±409.4, P=.048; LF/HF ratio: 3.3±2.4 to 2.6±1.5, P=.33]. After 3 months of treatment with gabapentin, some HRV parameters showed some improvement. SDNN (106.2±29.8 to 119.4 ± 25, P=.016) and HF (133.6±98.3 to 167.6±118.3, P=.021) increased significantly. LF/HF ratio decreased (from 3.3±2.4 to 2.3±1.9, P=.039) and LF remained unchanged (341.8±247.8 to 352.3±228.9, P=.88).

Conclusions

Therapeutic doses of gabapentin not only alleviate neuropathic symptoms but also improve cardiac autonomic function in diabetic patients with peripheral neuropathy.

Keywords: Gabapentin therapy, Heart rate variability, Diabetic peripheral neuropathy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1056-8727(08)00120-7

doi:10.1016/j.jdiacomp.2008.12.001

Journal of Diabetes and Its Complications
Volume 24, Issue 4 , Pages 229-233, July 2010